Login to Your Account

Other News To Note

Thursday, August 23, 2012
• Dynavax Technologies Corp., of Berkeley, Calif., said the European Medicines Agency (EMA) accepted the marketing authorization application (MAA) filing for Heplisav, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults, ages 18 to 70, and in patients with chronic kidney disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription